Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.03, read 2026-11-05
Ethical passes the values gate
Price13.54 USD
Fair value14.00
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-10-02Read Accumulation13.44+0.7% to today ✓Markup gives way to Accumulation after an 18% rise in 10 weeks
2026-07-27Read Markup11.42+18.6% to today ✓Distribution gives way to Markup after a 12% rise in 4 weeks
2026-07-02Read Distribution10.20+32.7% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
DoubleVerify Holdings, Inc. holds its Accumulation at $13.54. The statistical read favours the sellers, held for 50 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 50 days
Price at the screen
$13.54
Valuation
34.72 trailing · 11.59 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.91
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
7.35%
Below 33%
Interest-bearing debt is just 7.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
35.46%
Below 49%
Money owed to the company is 35.5% of assets, under the 49% limit.
Pass
Revenue purity
0.61%
Below 5%
Only 0.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
DoubleVerify Holdings, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 7%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DV's ethical verdict changes
Today DV passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades at roughly a 3% discount to our $14.00 fair value, 9.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 3.3% discount to the base estimate.
Where our models see it going: fair-value estimate $14.00, with a range of $14.00 to $27.08, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Ad Checks Trade Cheap Yet Deliver Weak Returns
Every digital ad needs someone to confirm it is not fraudulent or next to dodgy content. DoubleVerify supplies that check through its authenticity platform, yet the business is only growing revenue at 10 percent while posting a 7 percent profit margin and a 5 percent return on equity. At 9.3 times forward earnings the shares sit well below our fair value of 16 dollars, but the low returns and unknown competitive edge leave little reason to get excited.
We therefore pass. The market is not mispricing a high-quality compounder here. Instead it is correctly reflecting a modest growth profile and thin capital returns that do not justify stretching for the name even with an ethical screen that clears.
Currency moves, ad-spend cycles and the arrival of bigger rivals all sit in the risk column and could easily compress multiples further. Fifteen analysts still lean buy with a 14 dollar median target, yet that optimism rests on the same thin numbers we see today. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DV trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Accumulation$13.55+0.1%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (18 analysts) rates it buy, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Accumulation$13.54-0.1%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (18 analysts) rates it buy, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Accumulation$13.56+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (18 analysts) rates it buy, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$13.56+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (18 analysts) rates it buy, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$13.56+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (18 analysts) rates it buy, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$13.56-0.1%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (18 analysts) rates it buy, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$13.57+0.3%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (18 analysts) rates it buy, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$13.53-0.2%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (18 analysts) rates it buy, with a mean price target of $13. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$13.56+0.1%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (18 analysts) rates it buy, with a mean price target of $13.
2026-10-21Accumulation$13.54+0.4%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (18 analysts) rates it buy, with a mean price target of $13.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
